| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| | | |
| The Johns Hopkins Ovarian Cancer Center of Excellence acknowledges and thanks Aventis, Genzyme, GlaxoSmithKline, Oncotech, Ortho Biotech, and The Pam McDonald Fund for their support of this website through provision of unrestricted educational grants. |
|
 |
|
 |
|
Below are answers to previously submitted questions in the Ask the Expert Forum. Please note that the information is not indended to be used as medical advice -- please consult your physician with any medical concerns. |
| Category: BRCA mutations |
Q: I have a BRCA1 mutation. What are the current recommendations to assist in early conservative prophylaxis for my daughter?
A: Current recommendations would be for close surveillance as well as consideration of oral contraceptives (OCs). Studies have consistently shown that using OCs reduces the risk of ovarian cancer in the general population. In a 1992 analysis of 20 studies of OC use and ovarian cancer, researchers from Harvard Medical School found that the risk of ovarian cancer decreased with increasing duration of OC use. Results showed a 10 to 12 percent decrease in risk after 1 year of use, and approximately a 50 percent decrease after 5 years of use. More recent studies have demonstrated that the risk is also decreased in BRCA carriers as well.
I have provided a link to you so you can review the literature.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgiitool=abstractplus&db=pubmed&cmd =Retrieve&dopt=abstractplus&list_uids=15545966
|
|
|
